Found: 177
Select item for more details and to access through your institution.
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter
Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes.
- Published in:
- Diabetologia, 2021, v. 64, n. 7, p. 1583, doi. 10.1007/s00125-021-05426-2
- By:
- Publication type:
- Article
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
- By:
- Publication type:
- Article
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1226, doi. 10.1007/s00125-021-05399-2
- By:
- Publication type:
- Article
Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study.
- Published in:
- Diabetologia, 2018, v. 61, n. 12, p. 2570, doi. 10.1007/s00125-018-4720-1
- By:
- Publication type:
- Article
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
- Published in:
- Diabetologia, 2018, v. 61, n. 1, p. 58, doi. 10.1007/s00125-017-4422-0
- By:
- Publication type:
- Article
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
- By:
- Publication type:
- Article
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1932, doi. 10.1111/dom.15058
- By:
- Publication type:
- Article
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1453, doi. 10.1111/dom.14991
- By:
- Publication type:
- Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
- By:
- Publication type:
- Article
Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1117, doi. 10.1111/dom.14941
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1426, doi. 10.1111/dom.14352
- By:
- Publication type:
- Article
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 569, doi. 10.1111/dom.14254
- By:
- Publication type:
- Article
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 29, doi. 10.1111/dom.14179
- By:
- Publication type:
- Article
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2487, doi. 10.1111/dom.14160
- By:
- Publication type:
- Article
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1357, doi. 10.1111/dom.14041
- By:
- Publication type:
- Article
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1122, doi. 10.1111/dom.14011
- By:
- Publication type:
- Article
Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2440, doi. 10.1111/dom.13825
- By:
- Publication type:
- Article
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1625, doi. 10.1111/dom.13699
- By:
- Publication type:
- Article
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1437, doi. 10.1111/dom.13677
- By:
- Publication type:
- Article
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1073, doi. 10.1111/dom.13645
- By:
- Publication type:
- Article
Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 2, p. 261, doi. 10.1111/dom.13511
- By:
- Publication type:
- Article
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2379, doi. 10.1111/dom.13377
- By:
- Publication type:
- Article
DECLARE‐TIMI 58: Participants’ baseline characteristics.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1102, doi. 10.1111/dom.13217
- By:
- Publication type:
- Article
Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11).
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 53, doi. 10.1007/s13300-019-00715-x
- By:
- Publication type:
- Article
Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: From the Dallas Heart Study.
- Published in:
- Vascular Medicine, 2011, v. 16, n. 5, p. 339, doi. 10.1177/1358863X11422110
- By:
- Publication type:
- Article
Racial Disparity in Clinical Outcomes Following Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction: Influence of Process of Care.
- Published in:
- Journal of Interventional Cardiology, 2007, v. 20, n. 3, p. 182, doi. 10.1111/j.1540-8183.2007.00263.x
- By:
- Publication type:
- Article
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Metformin in Patients With Type 2 Diabetes and Kidney Disease.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 312, n. 24, p. 2668, doi. 10.1001/jama.2014.15298
- By:
- Publication type:
- Article
Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults.
- Published in:
- JAMA: Journal of the American Medical Association, 2012, v. 308, n. 11, p. 1150, doi. 10.1001/2012.jama.11132
- By:
- Publication type:
- Article
Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population.
- Published in:
- JAMA: Journal of the American Medical Association, 2010, v. 304, n. 22, p. 2503, doi. 10.1001/jama.2010.1768
- By:
- Publication type:
- Article
796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P
- By:
- Publication type:
- Article
791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-791-P
- By:
- Publication type:
- Article
788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-788-P
- By:
- Publication type:
- Article
786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P
- By:
- Publication type:
- Article
785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P
- By:
- Publication type:
- Article
783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P
- By:
- Publication type:
- Article
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
- Published in:
- 2021
- By:
- Publication type:
- journal article
162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-162-OR
- By:
- Publication type:
- Article
144-LB: Medicaid Expansion and Utilization of Antihyperglycemic Therapies.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-144-LB
- By:
- Publication type:
- Article
1224-P: Validation of a New Diabetes Staging System (DSS) for Type 2 Diabetes (T2D) Using Data from Three Cardiovascular Outcomes Trials (CVOTs).
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1224-P
- By:
- Publication type:
- Article
952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-952-P
- By:
- Publication type:
- Article
926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-926-P
- By:
- Publication type:
- Article
403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-403-P
- By:
- Publication type:
- Article
303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-303-OR
- By:
- Publication type:
- Article
1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1101-P
- By:
- Publication type:
- Article
1-OR: Analyses of First Plus Recurrent Cardiovascular (CV) and Hospitalization Events in the CAROLINA Trial.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1-OR
- By:
- Publication type:
- Article